Feature

The Rise of Private Equity in Gastroenterology Practices

Abstract: Private equity (PE) investment in gastroenterology practices has significantly increased over the past several years. Because PE firms are prevented legally from owning a medical […]

Feature

Advanced Combination Treatment With Biologic Agents and Novel Small Molecule Drugs for Inflammatory Bowel Disease

Abstract: The use of combination therapy with a biologic agent and immunosuppressant has well-established efficacy and safety and is common practice in the management of inflammatory […]

Advances in GERD

Potassium-Competitive Acid Blockers and Gastroesophageal Reflux Disease

G&H How do potassium-competitive acid blockers differ from proton pump inhibitors? DA Proton pump inhibitors (PPIs) are prodrugs that are not active as absorbed but are […]

Advances in Hepatology, Hepatology

Examining the New Definition of Hepatorenal Syndrome and the Role of Terlipressin

G&H How common is hepatorenal syndrome, and what are its potential consequences? RB Hepatorenal syndrome is the most serious complication of cirrhosis and portal hypertension and […]

Letter From the Editor

Letter From the Editor: Examining Race and Ethnicity in Patients With Inflammatory Bowel Disease

As Dr Marie L. Borum recounts in this month’s issue of Gastroenterology & Hepatology, it was frequently taught in the past that Black and Hispanic individuals […]

Advances in Endoscopy

Update on Barrett Esophagus Diagnosis and Management

G&H What has recent research revealed about the rise in esophageal adenocarcinoma despite screening and surveillance for Barrett esophagus? AC Esophageal adenocarcinoma (EAC) has been increasing […]

Advances in IBD

Racial and Ethnic Disparities in Inflammatory Bowel Disease

G&H What are the prevalence and incidence rates of inflammatory bowel disease by race and ethnicity, and how have they changed? MB The prevalence and incidence […]